A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
about
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategiesPerillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain MetastasesVorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK PathwaysResection versus radiosurgery for patients with brain metastases.Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of lifeTemozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).Temozolomide: a milestone in neuro-oncology and beyond?Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.Current management of metastatic brain diseaseThe role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors.Surgery of recurrent brain metastases: retrospective analysis of 67 patients.Chemotherapy for the treatment of metastatic brain tumors.A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrierBrain metastases in lung cancer.Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid.Treating brain metastases: current approaches and future directions.Current concepts and controversies in the treatment of parenchymal brain metastases: improved outcomes with aggressive management.Temozolomide: a milestone in the pharmacotherapy of brain tumors.Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.CNS metastasis in primary breast cancer.Temozolomide for treatment of brain metastases: A review of 21 clinical trials.The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guidelineBrain metastases: a medical neuro-oncology perspective.Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomideSalvage stereotactic radiosurgery for brain metastases.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.Systemic therapy of brain metastases.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.
P2860
Q24568071-40C1F4C2-182A-41BD-A81A-DBAFA0A732B6Q28072442-B6254973-8B79-4BEA-8B27-397A51810233Q28550980-D0CE6316-6D57-49D6-99D9-A2C6FB6A3357Q31097790-D7B38364-3663-45E1-B8EB-FD86AD48C7E1Q33270398-DC25F913-78E8-4C5F-9ABE-D1B5333CE3D0Q33370672-A6133B22-3799-4C1B-A6A6-A1EEBBE838BCQ33372340-F2E3A401-5082-45AD-9FC6-542B44D94B09Q33386298-3D2CD1B1-E725-4687-B068-AA9D48F29975Q33396761-748D091A-920A-489B-86E8-6D3972E7DB1EQ33409478-3C44CCF8-4DB5-4CF1-8319-B5F28A5A0786Q33475484-4DBBEEB5-BD55-4F92-B4A2-B7CF5E309EB6Q33599167-C7195281-AF93-4266-AE67-409DF4CD6F40Q33909294-0813EA2E-FE9B-4996-BCAC-E2D3F4706190Q34525981-E139736D-63A1-4272-9C0C-C441AB9BC4E5Q34872345-0029655E-9095-4279-8652-E5EE92B7504FQ34891770-DA836332-71A3-4336-AC7E-1C2E34DD7ABFQ34969177-B2BA2B5C-D964-4117-A0B8-67D210E8D684Q35030625-2427C73C-AB2E-428C-9FD1-B63460AECE62Q35728733-C61831A9-087D-4F8E-A29E-79622B56DC55Q35859267-E277E90E-9EA8-4B48-9C5F-985DA99A4A81Q36106920-9E07CC15-387A-4C7B-B4EB-7A0B64E589D8Q36229756-41FE953B-A39F-4F66-B87F-DA259B0E89D1Q36429611-5AF5B9F6-09A0-4E8D-A0BF-BAB6868E4482Q36682422-E915829D-AC40-4151-BCE1-D3EB8ED29B19Q37004668-FACA7859-3157-402F-AF78-BCD69F98455AQ37576025-4613E99F-23CF-4806-95BE-376A6E7F4419Q37643544-E3ECDB01-CD23-4C4E-A93B-42AD73A5F271Q37724219-F38B16B7-9BFB-4708-8B27-ACE6C71A04BDQ37870216-3B13D3C4-9861-4896-BE1B-EF82D9FE9339Q38036217-8FB4CA2E-D96C-45EA-B301-A1F159A02969Q38157039-A5E316EA-D8FA-485E-9C1F-94E578CCCB33Q38230553-0AFA2D06-31DD-4074-B6D4-8868F5A85614Q38285931-5B95A6A3-B820-4255-8F3C-8E3D253E378BQ38763111-5A459665-A796-42B6-8D24-9EECF4771E42Q38792519-FD2ADAED-5131-4D3D-9750-A0F5CDA0556BQ38888199-6EBDB3A7-7F6C-4D23-8072-38139633302BQ38985340-2A0CDABF-E595-44FA-A396-D65993E368B7Q39721426-37715C81-DFC0-4909-B271-754A381A5B88Q40308252-D3D7C2C1-9B16-48A0-A594-7EA9DA13D56FQ40636438-B4C9924E-B6FA-482D-A748-C962A50EB7FD
P2860
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A phase II trial of temozolomi ...... progressive brain metastases.
@ast
A phase II trial of temozolomi ...... progressive brain metastases.
@en
A phase II trial of temozolomi ...... progressive brain metastases.
@nl
type
label
A phase II trial of temozolomi ...... progressive brain metastases.
@ast
A phase II trial of temozolomi ...... progressive brain metastases.
@en
A phase II trial of temozolomi ...... progressive brain metastases.
@nl
prefLabel
A phase II trial of temozolomi ...... progressive brain metastases.
@ast
A phase II trial of temozolomi ...... progressive brain metastases.
@en
A phase II trial of temozolomi ...... progressive brain metastases.
@nl
P2093
P356
P1476
A phase II trial of temozolomi ...... progressive brain metastases.
@en
P2093
A Rodavitch
D Y Boutros
J J Raizer
M G Malkin
P2888
P304
P356
10.1023/A:1012226718323
P577
2001-07-01T00:00:00Z
P6179
1024326905